Loading clinical trials...
Loading clinical trials...
A Phase 4, Multicenter, Randomized, Placebo-controlled, Double-blind, Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate Plaque Psoriasis
Conditions
Interventions
Apremilast
Placebo
+1 more
Locations
26
United States
UAB at Birmingham - The Kirklin Clinic
Birmingham, Alabama, United States
Center For Dermatology
Fremont, California, United States
Dermatology Research Associates
Los Angeles, California, United States
Blue Harbor Dermatology
Newport Beach, California, United States
Center for Dermatology and Laser Surgery
Sacramento, California, United States
East Bay Rheumatology Medical
San Leandro, California, United States
Start Date
April 20, 2015
Primary Completion Date
February 12, 2016
Completion Date
November 22, 2016
Last Updated
June 5, 2023
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions